THE RELEVANCE OF ETHNIC INFLUENCES ON PHARMACOGENETICS TO THE TREATMENT OF PSYCHOSIS
- 1 September 2000
- journal article
- review article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 16 (1) , 15-38
- https://doi.org/10.1515/dmdi.2000.16.1.15
Abstract
Interethnic variation amongst the drug metabolising enzymes relevant to the treatment of psychosis is reviewed. The frequency of genetically determined variants at the extremes of enzyme activity is seen to vary considerably between different ethnic groups; in addition, a shift in the frequency distribution giving an overall lower population mean activity may occur. The role of dietary and other environmental influences in the generation of interethnic variation in cytochrome activity is also discussed. Clinical studies pertinent to this variation are reviewed. It is suggested that the reason for conflicting data from some clinical studies is the existence of overlapping substrate specificity, so that one cytochrome is able to substitute for another. Individuals deficient for more than one cytochrome would be likely to show much more pronounced clinical effects than those showing single cytochrome deficiency.Keywords
This publication has 68 references indexed in Scilit:
- Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of ChilePharmacogenetics, 1998
- High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypesPharmacogenetics, 1998
- A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activityBritish Journal of Clinical Pharmacology, 1996
- Pharmacokinetics, Metabolism and Interactions of Acid Pump InhibitorsClinical Pharmacokinetics, 1996
- Pharmacokinetics of Clozapine and RisperidoneJournal of Clinical Psychopharmacology, 1996
- Polymorphic Drug OxidationCNS Drugs, 1996
- Geographical/Interracial Differences in Polymorphic Drug OxidationClinical Pharmacokinetics, 1995
- The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and FilipinosPharmacogenetics, 1995
- Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean populationPharmacogenetics, 1993
- Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in NigeriansPharmacogenetics, 1992